<DOC>
	<DOCNO>NCT01951690</DOCNO>
	<brief_summary>This Phase II , open-label , multicenter , multi cohort , study VS-6063 ( defactinib ) , focal adhesion kinase inhibitor , patient KRAS mutant non-small cell lung cancer ( NSCLC ) . NSCLC KRAS mutation require study entry subject enrol 1 4 cohort base status INK4a/Arf p53 mutation . The purpose study demonstrate VS-6063 ( defactinib ) improve PFS within cohort . The safety tolerability VS-6063 , tumor response rate , progression free survival overall survival also assess . The pharmacodynamic effect VS-6063 ( defactinib ) examine tumor biopsy blood sample .</brief_summary>
	<brief_title>Phase II Study VS-6063 Patients With KRAS Mutant Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Eleven subject enrol one four cohort : Cohort A ( KRAS mutation , wild type INK4a/ARF wildtype p53 ) , Cohort B ( KRAS mutation , INK4s/ARF mutation wild type p53 ) , Cohort C ( KRAS mutation , wild type INK4a/ARF p53 mutation ) , Cohort D ( KRAS mutation , INK4a/ARF mutation p53 mutation ) . If &gt; /= 4 patient demonstrate PFS 12 week cohort , additional 23 subject enrol .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>≥ 18 year age . ECOG ( Eastern Cooperative Oncology Group ) Performance Score 0 1 . Histologic cytologic confirmation nonsmall cell lung cancer ( NSCLC ) Molecular characterization tumor demonstrate KRAS mutation CLIAcertified assay . Adequate archival tissue , tissue core biopsy specimen , DNA sample must available central test INK4a/Arf p53 previously perform CLIA certify lab . Documented evidence distant metastasis locoregional recurrence per require assessment within 28 day prior start study therapy . Note : Histologic confirmation metastatic disease require . For patient brain metastasis , follow criterion must meet : Previously untreated brain metastasis asymptomatic require steroid permit . Previously treat brain metastasis permit recent CNS radiographic image demonstrates evidence CNS disease progression For patient previously untreated brain metastasis , Central Nervous System ( CNS ) imaging required time disease image throughout treatment . At least one measurable disease site per RECIST v1.1 . Received minimum one course treatment include least one platinumbased chemotherapy doublet metastatic locally recurrent disease . Adequate hematologic function include ANC ≥ 1200/mm3 , Hemoglobin ≥ 9 g/dL ( transfusion permit ) , platelets ≥ 100,000/mm3 . Adequate hepatic function include ALT ≤ 2.5 x upper limit normal ( ULN ) liver metastasis NOT present ≤ 5 x ULN liver metastasis present , total bilirubin ≤ 1.5 x ULN . QTc ( correct QT ) interval &lt; 480 msec . Presence activate EGFR ( epidermal growth factor receptor ) mutation ALK ( anaplastic lymphoma kinase ) translocation tumor . Radiotherapy ( RT ) complete within 14 day prior first dose study therapy . Known impairment gastrointestinal function would alter drug absorption . Leptomeningeal metastasis . Symptomatic untreated brain metastasis spinal cord compression condition require chronic steroid control symptom . History evidence cardiac risk Known history malignant hypertension ( severe hypertension &gt; 180/120 mmHg end organ involvement . Another active concurrent malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Focal Adhesion Kinase inhibitor</keyword>
	<keyword>FAK inhibitor</keyword>
	<keyword>Cancer Stem Cells</keyword>
	<keyword>CSC</keyword>
	<keyword>KRAS mutation</keyword>
</DOC>